A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids.

Mason, R Preston; Walter, Mary F; Day, Charles A; Jacob, Robert F

Mason, R Preston; Walter, Mary F; Day, Charles A; Jacob, Robert F.

Affiliation

Mason RP; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Subcell Biochem ; 42: 175-90, 2007.

Article in En | MEDLINE | ID: mdl-17612051

Subject(s)

Atherosclerosis/chemically induced; Atherosclerosis/metabolism; Cell Membrane/metabolism; Cyclooxygenase 2 Inhibitors/toxicity; Lactones/toxicity; Lipid Peroxidation/drug effects; Lipoproteins, LDL/metabolism; Sulfones/toxicity; Humans; Naproxen/adverse effects; Prostaglandins I/biosynthesis; Risk Factors; Thromboxanes/biosynthesis

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Sulfones / Lipid Peroxidation / Cell Membrane / Atherosclerosis / Cyclooxygenase 2 Inhibitors / Lactones / Lipoproteins, LDL Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Subcell Biochem Year: 2007 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links